BridgeMD
New treatment option for Myeloma Multiple
Official title Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT07674498
What this study is testing
- What it's testing
- Relapsed/refractory multiple myeloma (RRMM) predominantly affects older adults, who exhibit marked heterogeneity in treatment outcomes despite receiving the same therapies. Clinical frailty scores, such as the International Myeloma Working Group (IMWG) Frailty Index, predict survival and treatment tolerance but provide limited information on immune competence, a key determinant of response to T-cell-based immunotherapies.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- ≥ 65 years old
- Relapsed/refractory multiple myeloma
- Eligible for a CAR-T cell or bispecific antibody therapies
You likely can't join if
- \<65 years old
- Active cancer other than myeloma
- Active AL amyloidosis
- Central nervous system (CNS) involvement
The study team makes the final eligibility decision.
Where it's taking place
- Anderlecht, Brussels Capital, Belgium
- Brussels, Brussels Capital, Belgium
- Woluwe-Saint-Lambert, Brussels Capital, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Anderlecht, Brussels Capital, Belgium; Brussels, Brussels Capital, Belgium; Woluwe-Saint-Lambert, Brussels Capital, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.